Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
On February 23, 2026, CNBC reported that Gilead Sciences announced it would acquire Arcellx, Inc. (NASDAQ:ACLX) for up to $7.8 billion to expand its cancer treatment pipeline.
Arcellx Inc. (ACLX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Alpine Associates Robert Emil Zoellner | 378,000 | $43,401,960 | 2.56% | |
| 2. | Jasper Ridge Partners Mark Wolfson And Jamie Alexander | 13,947 | $1,601,395 | 0.04% | |
| 3. | Kapitalo Investimentos Jo„O Carlos Pinho And Carlos Woelz | 7,978 | $916,034 | 0.17% | |
| 4. | BCK Capital Wayne Yu | 4,000 | $459,280 | 2% | |
| 5. | Bayforest Capital Theodoros Tsagaris | 375 | $43,058 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 312,500 | $5,000,000.00 | 6,745,262 | 2022-06-21 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing | |
| $15.00 | 66,667 | $1,000,005.00 | 3,466,811 | 2022-02-08 | Filing | |
| $15.00 | 1,583,333 | $23,749,995.00 | 6,432,762 | 2022-02-08 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $113.92 | 89,916 | $10,243,266.69 | 276,051 | 2026-02-27 | Filing | |
| $113.82 | 11,219 | $1,276,954.43 | 33,938 | 2026-02-25 | Filing | |
| $69.38 | 100 | $6,938.00 | 45,157 | 2026-02-19 | Filing | |
| $68.57 | 5,405 | $370,634.90 | 45,257 | 2026-02-19 | Filing | |
| $67.73 | 2,879 | $194,994.96 | 50,662 | 2026-02-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,720,803 | $771,682,600 | 36.44% | |
| 2. | 2,425,218 | $278,463,531 | 0.01% | |
| 3. | 2,424,818 | $278,417,603 | 0.01% | |
| 4. | 308,546 | $35,427,252 | 0.01% | |
| 5. | 223,486 | $25,660,663 | 84.07% |
News See All
12 Best Performing Stocks in February
On March 2, CNBC reported, citing a person familiar with the matter, billionaire investor Ken Griffin's Citadel hedge funds posted gains in February amid volatility stemming from artificial intelligence...
Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study
On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect
Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
On November 25, 2025, Arcellx, Inc. (NASDAQ:ACLX) saw Morgan Stanley’s Judah Frommer reiterate a “Buy” rating.
Hedge Fund Resource Center